Christopher Logothetis
Overview
Explore the profile of Christopher Logothetis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
4158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gregg J, Newcomb L, Wu R, Dennison J, Davis J, Pettaway C, et al.
Biomark Res
. 2024 Nov;
12(1):134.
PMID: 39522029
Background: We previously reported that increases in circulating sphingolipids are associated with elevated risk of biopsy Gleason grade group (GG) upgrading in men on Active Surveillance (AS) for prostate cancer....
2.
Fizazi K, Le Teuff G, Flechon A, Pagliaro L, Mardiak J, Geoffrois L, et al.
J Clin Oncol
. 2024 Aug;
42(28):3270-3276.
PMID: 39167741
JCO GETUG-13 established that switching patients with poor-prognosis nonseminomatous germ-cell tumors with an unfavorable marker decline to intensified chemotherapy resulted in improved outcomes. Here, we report the GETUG-13 long-term efficacy...
3.
Beckham T, Rooney M, Cifter G, Bernard V, McAleer M, De B, et al.
J Neurosurg Spine
. 2024 Jun;
41(3):436-444.
PMID: 38875722
Objective: Variation exists in approaches to delivery of spine stereotactic radiosurgery (SSRS). Here, the authors describe outcomes following single-fraction SSRS performed using a simultaneous integrated boost for the treatment of...
4.
Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa M, et al.
Eur Urol Oncol
. 2023 Oct;
6(6):611-620.
PMID: 37833193
Background: Neoadjuvant chemotherapy (neoCTX) has been recommended as the optimal strategy in surgically resectable neuroendocrine carcinoma (NEC) of the urinary tract (NEC-URO). Objective: To determine the systemic therapy regimen and...
5.
Logotheti S, Papadaki E, Zolota V, Logothetis C, Vrahatis A, Soundararajan R, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686633
Prostate cancer (PCa), the most frequent and second most lethal cancer type in men in developed countries, is a highly heterogeneous disease. PCa heterogeneity, therapy resistance, stemness, and lethal progression...
6.
Halabi S, Yang Q, Roy A, Luo B, Araujo J, Logothetis C, et al.
J Clin Oncol
. 2023 Apr;
41(15):2736-2746.
PMID: 37040594
Purpose: We have previously developed and externally validated a prognostic model of overall survival (OS) in men with metastatic, castration-resistant prostate cancer (mCRPC) treated with docetaxel. We sought to externally...
7.
Gillessen S, Bossi A, Davis I, de Bono J, Fizazi K, James N, et al.
Eur J Cancer
. 2023 Apr;
185:178-215.
PMID: 37003085
Background: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to...
8.
Vellano C, White M, Andrews M, Chelvanambi M, Witt R, Daniele J, et al.
Nature
. 2023 Jan;
613(7945):E3.
PMID: 36627494
No abstract available.
9.
Gregg J, Kim J, Logothetis C, Hanash S, Zhang X, Manyam G, et al.
Eur Urol Oncol
. 2022 Aug;
6(3):282-288.
PMID: 35995710
Background: Coffee intake may lower prostate cancer risk and progression, but postdiagnosis outcomes by caffeine metabolism genotype are not well characterized. Objective: To evaluate associations between coffee intake, caffeine metabolism...
10.
Bondaruk J, Jaksik R, Wang Z, Cogdell D, Lee S, Chen Y, et al.
iScience
. 2022 Jul;
25(7):104715.
PMID: 35811851
[This corrects the article DOI: 10.1016/j.isci.2022.104551.].